New drug cocktail aims to stop liver cancer recurrence

NCT ID NCT04639180

Ongoing Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether combining two drugs—camrelizumab (an immunotherapy) and rivoceranib (a targeted therapy)—can prevent liver cancer from coming back in patients at high risk of recurrence after curative surgery or ablation. About 687 participants will receive either the drug combination or active surveillance (no treatment). The main goal is to see if the combo extends the time before cancer returns.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab (an immunotherapy drug) and rivoceranib (a targeted therapy drug)
What this could lead to: If successful, this combination could become a new standard treatment to delay or prevent liver cancer from coming back after surgery or ablation.
What could go wrong: This is still an experimental approach; side effects from the drugs may be serious, and it is not yet known if the benefits outweigh the risks compared to simply watching and waiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Guangxi Medical University Affiliated Tumor Hospital

Nanjin, Guangzhou, China
Guizhou Cancer Hospital

Guiyang, Guizhou, China
Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China
Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.